GH Research PLC (GHRS): Price and Financial Metrics
GET POWR RATINGS... FREE!
GHRS Stock Price Chart Interactive Chart >
GHRS Price/Volume Stats
|Current price||$9.53||52-week high||$20.34|
|Prev. close||$9.25||52-week low||$8.46|
|Day high||$9.70||Avg. volume||23,978|
|50-day MA||$10.25||Dividend yield||N/A|
|200-day MA||$11.66||Market Cap||481.47M|
GH Research PLC (GHRS) Company Bio
GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that is being investigated in the Phase 2 part of an ongoing Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate that is in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was founded in 2018 and is based in Dublin, Ireland.
Most Popular Stories View All
GHRS Latest News Stream
|Loading, please wait...|
GHRS Latest Social Stream
View Full GHRS Social Stream
Latest GHRS News From Around the Web
Below are the latest news stories about GH RESEARCH PLC that investors may wish to consider to help them evaluate GHRS as an investment opportunity.
While market volatility has brough the bears out of hibernation, certain short-squeeze stocks could be a trap for the pessimists.
E ratio of -44.86.
DUBLIN, Ireland, Nov. 10, 2022 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the third quarter ended September 30, 2022 and gave updates on its business. Third Quarter 2022 Financial Highlights Cash position Cash was $256.9 million as of September 30, 2022, compared to $276.8 million as of December 31, 2021. We believe that our e
All four of our cannabis-related indexes were up last week, while only the partly-related Psychedelic Compounds index dropped again.
Wall Street Analysts See a 262% Upside in GH Research PLC (GHRS): Can the Stock Really Move This High?
The consensus price target hints at a 262% upside potential for GH Research PLC (GHRS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
GHRS Price Returns